A global, multicenter, double-blind, randomized, phase 3 registration study evaluating Lisaftoclax (APG-2575) in combination with azacitidine (AZA) in patients with newly diagnosed high-risk myelodysplastic syndrome (HR-MDS).
Principal Investigator
Dott.ssa Elena Crisà
Contact Information for Access
Phase
FASE III
Status
ATTIVO
Objective of the study
The objective of the study is to confirm that the Lisaftoclax+Azacitidine regimen is clinically superior to Azacitidine alone.
High-risk myelodysplastic syndrome.
ClinicalTrials.gov ID NCT06641414
Sponsor: Ascentage Pharma Group Inc.
Pathologies
Onco-hematological (hematological cancers/malignancies)
Medication
Lisaftoclax
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients with a new diagnosis of high-risk myelodysplastic syndrome.
View the full study Back to search page